"Designing Growth Strategies is in our DNA"

Antibody Drug Conjugate Therapeutics Market Size, Share and Global Trend By Mechanism of Action (HER2 Antibodies, CD30 Antibodies, Anti-CD33 Antibody, CD22 Antibody), By Disease Indication (Blood cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Geography Forecast till 2026

Region : Global | Report ID: FBI101172 | Status : Ongoing

 

KEY MARKET INSIGHTS

Antibody drug conjugate therapeutics are emerging as a potential method for the treatment of cancer. Antibody drug conjugate therapeutics are immunotherapy agents that use the potential cytotoxic molecule combined with the monoclonal antibodies through chemical linkers. This, in turn increases the ability of the drug to target the specific tumor cells. It is due to this advantage that antibody drug conjugate therapeutics have now become a hot area of research and investments.

Apart from commercially available products, there are many pipeline products that are being developed by prominent key players. For example, Asana BioSciences LLC. is developing ASN004, an antibody drug conjugate having the ability to selectively target 5T4 oncofetal antigen, which is expressed in malignant tumors. Also, many other pipeline products and strategic collaborations in this field will help the antibody drug conjugate therapeutics market to flourish at a global level.

To gain extensive insights into the market, Request for Customization


The strive to develop novel treatment and drugs for chronic disease such as cancer through increased R&D investment is a major factor driving the growth in global antibody drug conjugate therapeutics market. Also, the potential pipeline products and favorable health reimbursement are the factors that are estimated to fuel the global antibody drug conjugate therapeutics market during the forecast years. 


However, the high production cost associated with antibody drug conjugate and side effect from the drugs is the major factor that can hamper the growth in global antibody drug conjugate therapeutics market.


Key Players Covered


Some of the key players present in the global antibody drug conjugate therapeutics market are Pfizer Inc., Genentech, Seattle Genetics Inc., Synthon Holding B.V., ImmunoGen Inc., AbbVie Inc., Genentech, Inc., Bayer AG, F. Hoffmann-La Roche Ltd, and other players.


SEGMENTATION


























SEGMENTATION



 DETAILS



By Mechanism of Action



· HER2 Antibodies


· CD30 Antibodies


· Anti-CD33 Antibody


· CD22 Antibody



By Disease Indication



· Blood cancer


· Breast Cancer


· Ovarian Cancer


· Lung Cancer


· Brain Tumor


· Others



By Distribution Channel



· Hospital Pharmacy


· Retail Pharmacy


· Online Pharmacy



By Geography



· North America (USA and Canada)


· Europe (UK, Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)


· Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)


· Latin America (Brazil, Mexico and Rest of Latin America)


· Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa)



Among the segmentation of the global antibody drug conjugate therapeutics market, breast cancer accounted for the largest revenue owing to the prevalence of breast cancer cases, thus boosting the R&D in the development of drugs in the treatment of breast cancer.


Key Insights



  • Mechanism of action for key products

  • Patent analysis

  • Pipeline analysis

  • Advancement in antibody drug conjugate

  • Key mergers and acquisitions


Regional Analysis


Geographically the global antibody drug conjugate therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The antibody drug conjugate therapeutics market is anticipated to expand in North America during the forecast years owing to the favorable health reimbursement and increasing funding for research in antibody drug conjugate therapeutics. In Europe and Asia Pacific, the antibody drug conjugate therapeutics market is projected to expand by the end of 2025 owing to new product launch and increasing trend of strategic collaborations.


Key Industry Developments



  • In March 2019, AstraZeneca entered into collaboration agreement with Daiichi Sankyo Company, Limited, for trastuzumab deruxtecan (DS-8201), an antibody-drug conjugate (ADC) and potential new targeted medicine for cancer treatment.
  • In December 2018, Seattle Genetics Inc. received FDA approval for Adcetris for the treatment of lymphoma.

Antibody Drug Conjugate Therapeutics Market Size, Share and Global Industry Trend Forecast till 2026
  • Ongoing
  • 2019
  • 2016-2018

    CHOOSE LICENSE TYPE

  • 4850
    6850
    8850

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Healthcare Clients

Natus-Medical
novo-nordisk
DAEWOONG
Sedana-Cyan-Black-Tag
Ge-Healthcare

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.
X